Unknown

Dataset Information

0

Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.


ABSTRACT:

Background

Chemoradiotherapy (CRT) remains one of the most common cancer treatment modalities, and recent data suggest that CRT is maximally effective when there is generation of an anti-tumoral immune response. However, CRT has also been shown to promote immunosuppressive mechanisms which must be blocked or reversed to maximize its immune stimulating effects.

Methods

Therefore, using a preclinical model of human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC), we developed a clinically relevant therapy combining CRT and two existing immunomodulatory drugs: cyclophosphamide (CTX) and the small molecule inducible nitric oxide synthase (iNOS) inhibitor L-n6-(1-iminoethyl)-lysine (L-NIL). In this model, we treated the syngeneic HPV-HNSCC mEER tumor-bearing mice with fractionated (10 fractions of 3?Gy) tumor-directed radiation and weekly cisplatin administration. We compared the immune responses induced by CRT and those induced by combinatory treatment (CRT?+?CTX/L-NIL) with flow cytometry, quantitative multiplex immunofluorescence and by profiling immune-related gene expression changes.

Results

We show that combination treatment favorably remodels the tumor myeloid immune microenvironment including an increase in anti-tumor immune cell types (inflammatory monocytes and M1-like macrophages) and a decrease in immunosuppressive granulocytic myeloid-derived suppressor cells (MDSCs). Intratumoral T cell infiltration and tumor antigen specificity of T cells were also improved, including a 31.8-fold increase in the CD8+ T cell/ regulatory T cell ratio and a significant increase in tumor antigen-specific CD8+ T cells compared to CRT alone. CTX/LNIL immunomodulation was also shown to significantly improve CRT efficacy, leading to rejection of 21% established tumors in a CD8-dependent manner.

Conclusions

Overall, these data show that modulation of the tumor immune microenvironment with CTX/L-NIL enhances susceptibility of treatment-refractory tumors to CRT. The combination of tumor immune microenvironment modulation with CRT constitutes a translationally relevant approach to enhance CRT efficacy through enhanced immune activation.

SUBMITTER: Hanoteau A 

PROVIDER: S-EPMC6332704 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Chemoradiotherapy (CRT) remains one of the most common cancer treatment modalities, and recent data suggest that CRT is maximally effective when there is generation of an anti-tumoral immune response. However, CRT has also been shown to promote immunosuppressive mechanisms which must be blocked or reversed to maximize its immune stimulating effects.<h4>Methods</h4>Therefore, using a preclinical model of human papillomavirus (HPV)-associated head and neck squamous cell carcinom  ...[more]

Similar Datasets

| S-EPMC4623876 | biostudies-literature
| S-EPMC7293104 | biostudies-literature
| S-EPMC6693252 | biostudies-literature
| S-EPMC9279856 | biostudies-literature
| S-EPMC5965685 | biostudies-literature
| S-EPMC6839635 | biostudies-literature
| S-EPMC8464715 | biostudies-literature
| S-EPMC7560580 | biostudies-literature
| S-EPMC8114109 | biostudies-literature
| S-EPMC8253289 | biostudies-literature